Register Now

Laurus Labs’ US arm gets Form 483 from FDA after ‘adverse experience’ probe

The inspection focused on the subsidiary’s practices and procedures related to Laurus Labs’ marketed products worldwide. Shares of Laurus Labs Ltd ended at ₹571.45, down by ₹5.45, or 0.94%, on the BSE

Leave a Reply

Your email address will not be published. Required fields are marked *